KDM6A and plasma cell myeloma: However, KDM6A appears to function as a tumor suppressor (113), and recent results implicate KDM6A loss in bladder cancer progression (114) and resistance to the CD38 blocker daratumumab in multiple myeloma (115), potentially contraindicating the general use of KDM6A/B inhibitors.